VMS Vortex Metals Inc

VentriPoint Diagnostics ("VentriPoint") (TSX VENTURE:VPT), a company focused on
better ways to monitor right heart function in children and adults, today
announced the appointment of Amol S. Karnick as Vice-President, Sales and
Business Development. 


Commenting on the appointment, VentriPoint's CEO, Dr. George Adams stated, "This
announcement clearly illustrates we are ready to move aggressively on
commercializing our heart diagnostic technology. Amol was an important member of
the General Electric Ultrasound imaging group with responsibilities for mergers
and acquisitions. As well, he helped build a global sales and support group
focused on ultrasound technology. In short, he has the ideal skill set to
spearhead the launch of the VentriPoint Medical System ("VMS")."


Amol has over 18 years of medical imaging experience, which has included: 



--  Over 7 years experience at GE Healthcare in various roles, including
    mergers and acquisitions where he helped drive $150 million in imaging
    sales as well as integrating 4 companies. 
    
--  Chief Operating Officer for Sentinelle Medical Incorporated and General
    Manager at Ultrasonix Medical Corporation, both of which are focused on
    medical imaging. 
    
--  Global expertise and experience working with multiple cultures around
    the world. 
    
--  Masters in Electrical Engineering (ultrasound) from McGill University. 
    



About VentriPoint Diagnostics Ltd. VentriPoint has created a diagnostic
ultrasound tool to monitor patients with heart disease, a leading cause of death
in developed countries. VMS is the first cost-effective and accurate diagnostic
tool for measuring right ventricle heart function. Congenital heart disease in
children is the first application in a suite of applications for all major heart
diseases including pulmonary hypertension, cardiovascular disease and heart
failure - a multibillion dollar market potential. Canada and Europe (CE Mark)
have granted approval for the sale of its VMS diagnostic tool and a 510(k)
submission is currently being reviewed by the U.S. Federal Drug Administration.


FORWARD-LOOKING STATEMENTS: The statements made in this press release that are
not historical facts contain forward-looking information that involves risk and
uncertainties. All statements, other than statements of historical facts, which
address VentriPoint's expectations, should be considered forward-looking
statements. Such statements are based on management's exercise of business
judgment as well as assumptions made by and information currently available to
management. When used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar import, are
intended to identify any forward-looking statements. You should not place undue
reliance on these forward-looking statements. These statements reflect a current
view of future events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities regulatory
authorities. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results could differ
materially from those anticipated in these forward-looking statements. The
Corporation undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof, or to reflect the
occurrence of any unanticipated events. Although management believes that
expectations are based on reasonable assumptions, no assurance can be given that
these expectations will materialize.

Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jun 2024 to Jul 2024

Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jul 2023 to Jul 2024